Evidence map›Paper›PMID 33076329›Full record

ReviewInternational journal of molecular sciences2020

Molecular Mechanisms and Emerging Therapeutics for Osteoporosis.

Ji-Yoon Noh, Young Yang, Haiyoung Jung

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 6 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 6 syntheses or guidelines pooled it, 282 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pharmacological effects ofFrontiers in pharmacology · 2026
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pro-Osteogenic Effect of the Nutraceutical BlastiMin ComplexInternational journal of molecular sciences · 2024
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Review
  13. [A Study on the Relationship Between Cyclic Inflammatory Protein Fibroblast Growth Factor 21, Osteoporosis, and Fractures].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ji-Yoon NohImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea.
Young YangResearch Institute of Women's Health, Sookmyung Women's University, 100 Cheongparo47gil, Yongsan-Gu, Seoul 04310, Korea.ORCID 0000-0003-4239-0804
Haiyoung JungImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea.ORCID 0000-0003-0152-591X
Korea Research Institute of Bioscience and Biotechnology · KRSookmyung Women's University · KR

Funding

National Research Foundation of Korea 2020R1A2C2012467
6 · The paper itself

Abstract

Osteoporosis is the most common chronic metabolic bone disease. It has been estimated that more than 10 million people in the United States and 200 million men and women worldwide have osteoporosis. Given that the aging population is rapidly increasing in many countries, osteoporosis could become a global challenge with an impact on the quality of life of the affected individuals. Osteoporosis can be defined as a condition characterized by low bone density and increased risk of fractures due to the deterioration of the bone architecture. Thus, the major goal of treatment is to reduce the risk for fractures. There are several treatment options, mostly medications that can control disease progression in risk groups, such as postmenopausal women and elderly men. Recent studies on the basic molecular mechanisms and clinical implications of osteoporosis have identified novel therapeutic targets. Emerging therapies targeting novel disease mechanisms could provide powerful approaches for osteoporosis management in the future. Here, we review the etiology of osteoporosis and the molecular mechanism of bone remodeling, present current pharmacological options, and discuss emerging therapies targeting novel mechanisms, investigational treatments, and new promising therapeutic approaches.

Indexed as

Bone RemodelingAnimalsBone Density Conservation AgentsCalcium-Regulating Hormones and AgentsHumansOsteoporosisSelective Estrogen Receptor ModulatorsStem Cell TransplantationBone Density Conservation AgentsCalcium-Regulating Hormones and AgentsSelective Estrogen Receptor Modulatorsfracturemedicationmolecular mechanismnovel approachosteoporosis

Identifiers

PMID33076329
PMCPMC7589419
OpenAlexW3092959286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.